Oncolytics Appoints Steve Glover to Board, Promotes John McAdory to COO

Oncolytics Biotech Inc. announced the appointment of Steve Glover to its Board of Directors and the promotion of John McAdory to Chief Operating Officer. Mr. Glover brings extensive public company leadership and transaction experience, including his role in the $2 billion acquisition of Ambrx Biopharma by Johnson & Johnson. Mr. McAdory, who joined Oncolytics earlier this year, will now oversee clinical operations, development, preclinical research, and strategic business development initiatives, aiming to accelerate the company's growth and advance its immunotherapy platform.